New investigational antifungal agents for treating invasive fungal infections

Expert Opinion on Investigational Drugs

Volumn 9, Issue 8, 2000, Pages 1797-1813

  Hossain, M A ^a   Ghannoum, M A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

(1,3) D glucan; Amphotericin B; Drug resistance; Fungal infection; Lipopeptide; Nephrotoxicity; Therapeutic index; Triazole

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; 4 [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 [4 (TRIFLUOROMETHOXY)BENZYL] 1,2,4 TRIAZOL 3 ONE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CHOLESTEROL; CYTOCHROME P450; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; IMIDAZOLE; ITRACONAZOLE; MANNAN; NEW DRUG; NYSTATIN; PHOSPHOLIPID; POLYENE; POLYSACCHARIDE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; SQUALENE; TRIAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; ZYMOSTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MYCOSIS; NONHUMAN; PHARMACEUTICAL ENGINEERING; RABBIT; RAT; REVIEW; SPECTRUM; SYSTEMIC DISEASE;

EID: 0033869904     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.8.1797     Document Type: Review

References (118)

1. Nosocomial fungal infections. Old problems and new challenges
2. Fungal infections: A growing threat
3. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
4. Developments in hyalohyphomycosis and phaeohyphomycosis
5. Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): Case report
6. The effects of the polyene antibiotics nystatin and amphotericin B on thin lipid membranes
7. The protoplast membrane and antifungal drugs
8. Amphotericin B: 30 years of clinical experience
9. Amphotericin B overdose in pediatric patients with associated cardiac arrest
10. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties
11. Carrier effects on biological activity of amphotericin B
12. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
13. A comparative review of conventional and lipid formulations of amphotericin B
14. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 α-sterol demethylase purified from Candida albicans
15. Oral azole drugs as systemic antifungal therapy
16. Use of azoles for systemic antifungal therapy
17. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans
18. Does long-term itraconazole prophylaxis result in In vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?
19. Molecular mechanisms of drug resistance in fungi
20. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals
21. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity
22. Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata
23. In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata
24. Antifungal agents: Mode of action, mechanisms of resistance and correlation of these mechanisms with bacterial resistance
25. Overview of oral azole drugs as systemic antifungal therapy
26. Mode of action of 5-fluorocytosine and mechanisms of resistance
27. Mode of action of 5-fluorocytosine
28. Formulation, toxicity and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis
29. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections
30. Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma
31. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex and itraconazole
32. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits
33. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with amphotericin B
34. Pharmacokinetics of liposomal nystatin in patients with human immuno-deficiency virus infection
35. In vitro antifungal activity of Nyotran against clinical isolates
36. An in vitro interaction study with Nyotran (liposomal Nystatin) and conventional antifungals, antibiotics, antivirals and immunosuppressive drugs against common fungal pathogens
37. Mild heating of amphotericin B-desoxycholate: Effects on ultrastructure. In vitro activity and toxicity and therapeutic efficacy in severe candidiasis in leukopenic mice
38. Amphotericin B in lipid emulsion: Stability, compatibility and in vitro antifungal activity
39. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice
40. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients
41. A new antifungal drug delivery system, lipid nanosphere encapsulating amphotericin B (LNS-AmB), its evaluation in the rat model of invasive pulmonary aspergillosis
42. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans
43. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus
44. Attenuation of nephrotoxicity by a novel lipid nanosphere incorporating amphotericin B, NS-718
45. Amphotericin B liposomes with prolonged circulation in blood: In vitro antifungal activity, toxicity and efficacy in systemic candidiasis in leukopenic mice
46. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice
47. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model
48. Voriconazole (UK-109, 496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
49. Effects of voriconazole on Candida glabrata in vitro
50. Voriconazole against fluconazole-susceptible and resistant Candida isolates: In-vitro efficacy compared with that of itraconazole and ketoconazole
51. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
52. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs. var. neoformans: Comparison with fluconazole and effect of human serum
53. Activity of voriconazole: Post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes
54. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
55. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
56. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole
57. In vitro activities of voriconazole, fluconazole and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
58. In vitro activity of voriconazole against selected fungi
59. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells
60. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model
61. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS
62. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive Aspergillosis
63. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
64. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
65. Efficacy of SCH 56592 in a temporarily neutropenic murine model of invasive Aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
66. In vitro activity of SCH 56592 against Blastomyces dermatitidis
67. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis
68. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice
69. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens
70. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans
71. SCH56592 treatment of murine invasive aspergillosis
72. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis
73. Treatment of murine fusariosis with SCH 56592
74. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains
75. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ('Ramichloridium mackenziei')
76. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs and cynomolgus monkeys
77. In vitro activity of a new oral triazole, BMS-207147 (ER-30346) Antimicrob
78. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592 and voriconazole
79. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole
80. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
81. Efficacy of a new triazole, BMS-207174, in a model of invasive aspergillosis in immunosuppressed, neutropenic rabbits
82. Efficacy of BMS-207147 on Trichophyton mentagrophytes-Dermatophytosis in guinea pig model
83. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A
84. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens
85. In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans
86. Evidence for a glycosidic linkage between chitin and glucan in the cell wall of Candida albicans
87. Comparison between Wako-WB003 and Fungitec G tests for detection of (1→3)-β-D-glucan in systemic mycosis
88. Detection of plasma (1→3)-β-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias
89. Antibiotics that inhibit fungal cell wall development
90. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi
91. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
92. Treatment of histoplasmosis with MK-991 (L-743,872)
93. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
94. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991 and fluconazole against Candida species and Cryptococcus neoformans
95. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits
96. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
97. Antifungal efficacy, safety and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
98. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo
99. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
100. Efficacy of FK463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice
101. In vitro activity of A-192411.29, a novel antifungal lipopeptide
102. Mulundocandin, an echinocandin-like lipopeptide antifungal agent: Biological activities in vitro
103. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis and blastomycosis
104. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis
105. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole
106. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis
107. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model
108. Antifungal antibiotic benanomicin A increases susceptibility of Candida albicans to phagocytosis by murine macrophages
109. Binding of benanomicin A to fungal cells in reference to its fungicidal action
110. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184
111. Activity of pradimicin BMS-181184 against Aspergillus spp
112. The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B
113. The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole
114. Peptide antibiotics
115. Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro
116. In vitro antifungal activity and cytotoxicity of a novel membrane-active peptide
117. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5 and salivary mucin (MUC7) domain 1
118. Activities of sordarins in murine histoplasmosis